Balsalazide disodium salt dihydrate
CAS: 150399-21-6
Ref. 3D-FB61545
1g | Discontinued | ||
2g | Discontinued | ||
5g | Discontinued | ||
10g | Discontinued | ||
500mg | Discontinued |
Product Information
- (E)-5-[[4-[[(2-CARBOXYETHYL)AMINO]CARBONYL]PHENYL]AZO]-2-HYDROXYBENZOIC ACID, DISODIUM SALT, dihydrate
- (E)-5-[[p-[(2-Carboxyethyl)carbamoyl]phenyl]azo]salicylic acid,disodium salt,dihydrate
- Balsalazide Disodium 2-Hydrate
- Balsalazide disodium hydrate
- Benzoic acid, 5-[(1E)-2-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]diazenyl]-2-hydroxy-, sodium salt, hydrate (1:2:2)
- Benzoic acid, 5-[(1E)-[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]azo]-2-hydroxy-, disodium salt, dihydrate
- Benzoic acid, 5-[[4-[[(2-carboxyethyl)amino]carbonyl]phenyl]azo]-2-hydroxy-, disodium salt, dihydrate, (E)-
- disodium (3Z)-3-({4-[(2-carboxylatoethyl)carbamoyl]phenyl}hydrazono)-6-oxocyclohexa-1,4-diene-1-carboxylate dihydrate
Balsalazide is a drug that belongs to the group of drugs used to treat bowel disease. It is used in children for the treatment of colitis and other inflammatory bowel diseases. Balsalazide is a prodrug that is converted into balsalazide by the enzyme, carboxypeptidase A2, which releases the active form from its peptide bond. Balsalazide inhibits the production of IL-2 receptor and calcium pantothenate in vitro, which may be due to its ability to bind to these proteins and prevent their interaction with cofactors. This drug has been shown to be effective in both clinical trials and control analysis studies with ulcerative colitis patients.